U.S. Markets closed

Compugen Ltd. (CGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.57-0.33 (-3.71%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.66
Open8.77
Bid8.90 x 900
Ask8.96 x 1100
Day's Range8.63 - 8.96
52 Week Range7.10 - 19.90
Volume835,832
Avg. Volume1,483,088
Market Cap684.009M
Beta (5Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.29
  • Did Compugen's (NASDAQ:CGEN) Share Price Deserve to Gain 94%?
    Simply Wall St.

    Did Compugen's (NASDAQ:CGEN) Share Price Deserve to Gain 94%?

    The Compugen Ltd. ( NASDAQ:CGEN ) share price is down a rather concerning 39% in the last month. But over three years...

  • Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
    PR Newswire

    Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

    Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis" reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen's Scientific Advisory Board.

  • Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference
    PR Newswire

    Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

    Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET.